Stem Cell Evidence
@stemcellevidence.bsky.social
Curating the evidence in haematopoietic stem cell transplantation. Free monthly Stem Cell Evidence Alert http://bit.ly/2HMQtb5 @stemcellevidence@fediscience.org
#MedSky
#MedSky
Pinned
The #StemCellEvidence monthly alert is out!
See the top 10 articles, read the PICO summaries, and subscribe to this alert here:
www.stemcellevidence.com/alerts/latest
#MedSky
See the top 10 articles, read the PICO summaries, and subscribe to this alert here:
www.stemcellevidence.com/alerts/latest
#MedSky
New from the #StemCellEvidence Alert:
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation (...)
by Sanz et al.
www.stemcellevidence.com/articles/411...
#MedSky
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation (...)
by Sanz et al.
www.stemcellevidence.com/articles/411...
#MedSky
January 7, 2026 at 7:54 AM
New from the #StemCellEvidence Alert:
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation (...)
by Sanz et al.
www.stemcellevidence.com/articles/411...
#MedSky
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation (...)
by Sanz et al.
www.stemcellevidence.com/articles/411...
#MedSky
From the #StemCellEvidence Alert:
Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide (...)
by Rocha et al.
www.stemcellevidence.com/articles/411...
#MedSky
Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide (...)
by Rocha et al.
www.stemcellevidence.com/articles/411...
#MedSky
January 6, 2026 at 6:39 PM
From the #StemCellEvidence Alert:
Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide (...)
by Rocha et al.
www.stemcellevidence.com/articles/411...
#MedSky
Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide (...)
by Rocha et al.
www.stemcellevidence.com/articles/411...
#MedSky
Reposted by Stem Cell Evidence
From the #Transfusion Evidence Alert:
Comparative efficacy and safety of prothrombin complex concentrate versus fresh frozen plasma in #cardiacsurgery: A #metaanalysis of randomized controlled trials
by Khan et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
Comparative efficacy and safety of prothrombin complex concentrate versus fresh frozen plasma in #cardiacsurgery: A #metaanalysis of randomized controlled trials
by Khan et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
January 6, 2026 at 6:31 PM
From the #Transfusion Evidence Alert:
Comparative efficacy and safety of prothrombin complex concentrate versus fresh frozen plasma in #cardiacsurgery: A #metaanalysis of randomized controlled trials
by Khan et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
Comparative efficacy and safety of prothrombin complex concentrate versus fresh frozen plasma in #cardiacsurgery: A #metaanalysis of randomized controlled trials
by Khan et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
New from the #StemCellEvidence Alert:
Belumosudil for Chronic Graft-Versus-Host Disease: A #SystematicReview and #Meta-Analysis
by Rathje et al.
www.stemcellevidence.com/articles/412...
#MedSky
Belumosudil for Chronic Graft-Versus-Host Disease: A #SystematicReview and #Meta-Analysis
by Rathje et al.
www.stemcellevidence.com/articles/412...
#MedSky
January 5, 2026 at 11:18 AM
New from the #StemCellEvidence Alert:
Belumosudil for Chronic Graft-Versus-Host Disease: A #SystematicReview and #Meta-Analysis
by Rathje et al.
www.stemcellevidence.com/articles/412...
#MedSky
Belumosudil for Chronic Graft-Versus-Host Disease: A #SystematicReview and #Meta-Analysis
by Rathje et al.
www.stemcellevidence.com/articles/412...
#MedSky
Reposted by Stem Cell Evidence
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Blood component therapy for dry eye disease: a #systematicreview and network #meta-analysis
by Zhang et al.
www.transfusionevidencelibrary.com/articles/397...
#MedSky
@isbt.bsky.social
Blood component therapy for dry eye disease: a #systematicreview and network #meta-analysis
by Zhang et al.
www.transfusionevidencelibrary.com/articles/397...
#MedSky
@isbt.bsky.social
January 2, 2026 at 3:48 PM
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Blood component therapy for dry eye disease: a #systematicreview and network #meta-analysis
by Zhang et al.
www.transfusionevidencelibrary.com/articles/397...
#MedSky
@isbt.bsky.social
Blood component therapy for dry eye disease: a #systematicreview and network #meta-analysis
by Zhang et al.
www.transfusionevidencelibrary.com/articles/397...
#MedSky
@isbt.bsky.social
New from the #StemCellEvidence Alert:
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse
by Murdock et al.
www.stemcellevidence.com/articles/411...
#MedSky
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse
by Murdock et al.
www.stemcellevidence.com/articles/411...
#MedSky
January 2, 2026 at 4:04 PM
New from the #StemCellEvidence Alert:
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse
by Murdock et al.
www.stemcellevidence.com/articles/411...
#MedSky
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse
by Murdock et al.
www.stemcellevidence.com/articles/411...
#MedSky
From the #StemCellEvidence Alert:
Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan
by Konuma et al.
www.stemcellevidence.com/articles/408...
#MedSky
Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan
by Konuma et al.
www.stemcellevidence.com/articles/408...
#MedSky
December 31, 2025 at 10:53 AM
From the #StemCellEvidence Alert:
Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan
by Konuma et al.
www.stemcellevidence.com/articles/408...
#MedSky
Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan
by Konuma et al.
www.stemcellevidence.com/articles/408...
#MedSky
Reposted by Stem Cell Evidence
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Efficacy and safety of different treatments in chemotherapy-induced thrombocytopenia: a #systematicreview and network #metaanalysis
by Yang et al.
#MedSky
@isbt.bsky.social
Efficacy and safety of different treatments in chemotherapy-induced thrombocytopenia: a #systematicreview and network #metaanalysis
by Yang et al.
#MedSky
@isbt.bsky.social
December 31, 2025 at 10:46 AM
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Efficacy and safety of different treatments in chemotherapy-induced thrombocytopenia: a #systematicreview and network #metaanalysis
by Yang et al.
#MedSky
@isbt.bsky.social
Efficacy and safety of different treatments in chemotherapy-induced thrombocytopenia: a #systematicreview and network #metaanalysis
by Yang et al.
#MedSky
@isbt.bsky.social
Reposted by Stem Cell Evidence
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
#Tranexamicacid for preventing postpartum haemorrhage after vaginal birth
by Rohwer et al.
www.transfusionevidencelibrary.com/articles/398...
#MedSky
#Tranexamicacid for preventing postpartum haemorrhage after vaginal birth
by Rohwer et al.
www.transfusionevidencelibrary.com/articles/398...
#MedSky
December 30, 2025 at 10:58 AM
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
#Tranexamicacid for preventing postpartum haemorrhage after vaginal birth
by Rohwer et al.
www.transfusionevidencelibrary.com/articles/398...
#MedSky
#Tranexamicacid for preventing postpartum haemorrhage after vaginal birth
by Rohwer et al.
www.transfusionevidencelibrary.com/articles/398...
#MedSky
New from the #StemCellEvidence Alert:
Analyses of transplantation outcomes for adult patients with mixed-phenotype acute leukemia
y Jo et al.
www.stemcellevidence.com/articles/411...
#MedSky
Analyses of transplantation outcomes for adult patients with mixed-phenotype acute leukemia
y Jo et al.
www.stemcellevidence.com/articles/411...
#MedSky
December 30, 2025 at 11:10 AM
New from the #StemCellEvidence Alert:
Analyses of transplantation outcomes for adult patients with mixed-phenotype acute leukemia
y Jo et al.
www.stemcellevidence.com/articles/411...
#MedSky
Analyses of transplantation outcomes for adult patients with mixed-phenotype acute leukemia
y Jo et al.
www.stemcellevidence.com/articles/411...
#MedSky
Reposted by Stem Cell Evidence
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Darbepoetin alfa to reduce transfusion episodes in infants with haemolytic disease of the fetus and newborn (...)
by Ree et al.
www.transfusionevidencelibrary.com/articles/380...
#MedSky
Darbepoetin alfa to reduce transfusion episodes in infants with haemolytic disease of the fetus and newborn (...)
by Ree et al.
www.transfusionevidencelibrary.com/articles/380...
#MedSky
December 29, 2025 at 12:13 PM
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Darbepoetin alfa to reduce transfusion episodes in infants with haemolytic disease of the fetus and newborn (...)
by Ree et al.
www.transfusionevidencelibrary.com/articles/380...
#MedSky
Darbepoetin alfa to reduce transfusion episodes in infants with haemolytic disease of the fetus and newborn (...)
by Ree et al.
www.transfusionevidencelibrary.com/articles/380...
#MedSky
From the #StemCellEvidence Alert:
Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT
by Barbullushi et al.
www.stemcellevidence.com/articles/412...
#MedSky
Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT
by Barbullushi et al.
www.stemcellevidence.com/articles/412...
#MedSky
December 29, 2025 at 12:17 PM
From the #StemCellEvidence Alert:
Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT
by Barbullushi et al.
www.stemcellevidence.com/articles/412...
#MedSky
Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT
by Barbullushi et al.
www.stemcellevidence.com/articles/412...
#MedSky
New from the #StemCellEvidence Alert:
The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD
by Akahoshi et al.
www.stemcellevidence.com/articles/408...
#MedSky
The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD
by Akahoshi et al.
www.stemcellevidence.com/articles/408...
#MedSky
December 26, 2025 at 1:04 PM
New from the #StemCellEvidence Alert:
The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD
by Akahoshi et al.
www.stemcellevidence.com/articles/408...
#MedSky
The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD
by Akahoshi et al.
www.stemcellevidence.com/articles/408...
#MedSky
Reposted by Stem Cell Evidence
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Rice-derived recombinant human serum albumin as an alternative to human plasma (...)
by Niu et al.
www.transfusionevidencelibrary.com/articles/405...
#MedSky
@isbt.bsky.social
Rice-derived recombinant human serum albumin as an alternative to human plasma (...)
by Niu et al.
www.transfusionevidencelibrary.com/articles/405...
#MedSky
@isbt.bsky.social
December 26, 2025 at 12:58 PM
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Rice-derived recombinant human serum albumin as an alternative to human plasma (...)
by Niu et al.
www.transfusionevidencelibrary.com/articles/405...
#MedSky
@isbt.bsky.social
Rice-derived recombinant human serum albumin as an alternative to human plasma (...)
by Niu et al.
www.transfusionevidencelibrary.com/articles/405...
#MedSky
@isbt.bsky.social
Reposted by Stem Cell Evidence
From the #Transfusion Evidence Alert:
Transfusion thresholds and other strategies for guiding red blood cell transfusion
by Carson et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
Transfusion thresholds and other strategies for guiding red blood cell transfusion
by Carson et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
December 22, 2025 at 7:44 AM
From the #Transfusion Evidence Alert:
Transfusion thresholds and other strategies for guiding red blood cell transfusion
by Carson et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
Transfusion thresholds and other strategies for guiding red blood cell transfusion
by Carson et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
From the #StemCellEvidence Alert:
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis
by Mehta et al.
www.stemcellevidence.com/articles/411...
#MedSky
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis
by Mehta et al.
www.stemcellevidence.com/articles/411...
#MedSky
December 22, 2025 at 7:39 AM
From the #StemCellEvidence Alert:
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis
by Mehta et al.
www.stemcellevidence.com/articles/411...
#MedSky
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis
by Mehta et al.
www.stemcellevidence.com/articles/411...
#MedSky
Reposted by Stem Cell Evidence
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study
by Kuter et al.
www.transfusionevidencelibrary.com/articles/400...
#MedSky
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study
by Kuter et al.
www.transfusionevidencelibrary.com/articles/400...
#MedSky
December 22, 2025 at 7:29 AM
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study
by Kuter et al.
www.transfusionevidencelibrary.com/articles/400...
#MedSky
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study
by Kuter et al.
www.transfusionevidencelibrary.com/articles/400...
#MedSky
The #StemCellEvidence monthly alert is out!
See the top 10 articles, read the PICO summaries, and subscribe to this alert here:
www.stemcellevidence.com/alerts/latest
#MedSky
See the top 10 articles, read the PICO summaries, and subscribe to this alert here:
www.stemcellevidence.com/alerts/latest
#MedSky
December 19, 2025 at 9:58 AM
The #StemCellEvidence monthly alert is out!
See the top 10 articles, read the PICO summaries, and subscribe to this alert here:
www.stemcellevidence.com/alerts/latest
#MedSky
See the top 10 articles, read the PICO summaries, and subscribe to this alert here:
www.stemcellevidence.com/alerts/latest
#MedSky
Reposted by Stem Cell Evidence
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa (...)
by Garcia-Manero et al.
www.transfusionevidencelibrary.com/articles/403...
#MedSky
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa (...)
by Garcia-Manero et al.
www.transfusionevidencelibrary.com/articles/403...
#MedSky
December 19, 2025 at 7:43 AM
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa (...)
by Garcia-Manero et al.
www.transfusionevidencelibrary.com/articles/403...
#MedSky
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa (...)
by Garcia-Manero et al.
www.transfusionevidencelibrary.com/articles/403...
#MedSky
Reposted by Stem Cell Evidence
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE) (...)
by Taher et al.
www.transfusionevidencelibrary.com/articles/405...
#MedSky
@isbt.bsky.social
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE) (...)
by Taher et al.
www.transfusionevidencelibrary.com/articles/405...
#MedSky
@isbt.bsky.social
December 16, 2025 at 10:05 AM
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE) (...)
by Taher et al.
www.transfusionevidencelibrary.com/articles/405...
#MedSky
@isbt.bsky.social
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE) (...)
by Taher et al.
www.transfusionevidencelibrary.com/articles/405...
#MedSky
@isbt.bsky.social
From the #StemCellEvidence Alert:
Predicting cardiovascular events in allogeneic hematopoietic stem cell transplant recipients
by Sibilia et al.
www.stemcellevidence.com/articles/410...
#MedSky
Predicting cardiovascular events in allogeneic hematopoietic stem cell transplant recipients
by Sibilia et al.
www.stemcellevidence.com/articles/410...
#MedSky
December 4, 2025 at 7:23 AM
From the #StemCellEvidence Alert:
Predicting cardiovascular events in allogeneic hematopoietic stem cell transplant recipients
by Sibilia et al.
www.stemcellevidence.com/articles/410...
#MedSky
Predicting cardiovascular events in allogeneic hematopoietic stem cell transplant recipients
by Sibilia et al.
www.stemcellevidence.com/articles/410...
#MedSky
Reposted by Stem Cell Evidence
From the #Transfusion Evidence Alert:
BiZact versus cold steel for post-tonsillectomy hemorrhage: a multicenter randomized trial
by Mølhave et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
BiZact versus cold steel for post-tonsillectomy hemorrhage: a multicenter randomized trial
by Mølhave et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
December 4, 2025 at 6:47 AM
From the #Transfusion Evidence Alert:
BiZact versus cold steel for post-tonsillectomy hemorrhage: a multicenter randomized trial
by Mølhave et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
BiZact versus cold steel for post-tonsillectomy hemorrhage: a multicenter randomized trial
by Mølhave et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
New from #StemCellEvidence:
Don't fly and freeze: impact of ex vivo time, cell density and cryopreservation on allogeneic stem cell grafts
by Novitzky-Basso et al.
www.stemcellevidence.com/articles/410...
#MedSky
Don't fly and freeze: impact of ex vivo time, cell density and cryopreservation on allogeneic stem cell grafts
by Novitzky-Basso et al.
www.stemcellevidence.com/articles/410...
#MedSky
December 3, 2025 at 6:48 AM
New from #StemCellEvidence:
Don't fly and freeze: impact of ex vivo time, cell density and cryopreservation on allogeneic stem cell grafts
by Novitzky-Basso et al.
www.stemcellevidence.com/articles/410...
#MedSky
Don't fly and freeze: impact of ex vivo time, cell density and cryopreservation on allogeneic stem cell grafts
by Novitzky-Basso et al.
www.stemcellevidence.com/articles/410...
#MedSky
Reposted by Stem Cell Evidence
From the #Transfusion Evidence Alert:
Restrictive transfusion in acute brain injury: A #metaanalysis of randomized clinical trials
by Machado et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
Restrictive transfusion in acute brain injury: A #metaanalysis of randomized clinical trials
by Machado et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
December 2, 2025 at 12:00 PM
From the #Transfusion Evidence Alert:
Restrictive transfusion in acute brain injury: A #metaanalysis of randomized clinical trials
by Machado et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
Restrictive transfusion in acute brain injury: A #metaanalysis of randomized clinical trials
by Machado et al.
www.transfusionevidencelibrary.com/alerts/artic...
#MedSky
From the #StemCellEvidence Alert:
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial
by Mohty et al.
www.stemcellevidence.com/articles/410...
#MedSky
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial
by Mohty et al.
www.stemcellevidence.com/articles/410...
#MedSky
December 2, 2025 at 11:42 AM
From the #StemCellEvidence Alert:
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial
by Mohty et al.
www.stemcellevidence.com/articles/410...
#MedSky
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial
by Mohty et al.
www.stemcellevidence.com/articles/410...
#MedSky